Radiopharm Theranostics RADX
NASDAQ RADX
$0.88 -0.07 (-7.70%)
At close: Nov 9, 2026 · 4:00 PM EST

Radiopharm Theranostics (RADX) Receivables - Net (2023 - 2026)

Updated

Radiopharm Theranostics (RADX) reported Receivables - Net of $123,764 for fiscal Q4 2026 (quarter ended Jun 30, 2026), up 85.8% from $66,605 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Receivables - Net (2023 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics posted Receivables - Net of $118,496, down 98.9% from FY2025.

  • Receivables - Net has a three-year compound annual growth rate of -70.2% (FY2023 to FY2026).
  • By fiscal year, Receivables - Net came in at $10.4 million in FY2025 (+953.3%), $987,413 in FY2024 (-77.9%) and $4.47 million in FY2023.
  • The fiscal Q4 2026 figure ranks as the highest quarterly Receivables - Net since fiscal Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Radiopharm Theranostics 2.70 Bn 2.62 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 17.45 Mn
Jun 30, 2025 10.40 Mn
Dec 31, 2024 6.25 Mn
Jun 30, 2024 987,413.00
Jun 30, 2023 4.47 Mn
API Access

Radiopharm Theranostics Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=RADX&period=max&api_key=YOUR_API_KEY